BH-501284 / BlossomHill Therap - LARVOL DELTA

BlossomHill Therapeutics reports Q2 2026 net loss $23.8M, cash $95.4M; completed $168.3M IPO (TradingView) - "BH-501284: Presented first preclinical data for the pseudo-irreversible pan-KRAS inhibitor...IND-enabling work underway with an anticipated IND submission in Q1 2027."

IND • Solid Tumor

BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger (FierceBiotech) - "A total of $70 million of this IPO cash has been earmarked for the company’s lead asset, a macrocyclic EGFR-targeting molecule called BH-30643...the biotech intending to use some of this sum to launch a 'potentially registrational' phase 2 trial...Meanwhile, around $20 million of the IPO haul will be used to push ahead with a phase 1 study of BH-30236, which the company is pitching as the first drug to successfully target a CDC-like kinase. The study is enrolling patients with relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndrome...There’s also $5 million that will be set aside to take the pan-KRAS inhibitor BH-501284 from IND-enabling studies into the clinic."

Financing • Acute Myelogenous Leukemia • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Solid Tumor

Discovery and characterization of BH-501284: A non-covalent, pan-KRAS inhibitor for treatment of diverse KRAS-mutant tumors (AACR 2026) - "Lastly, BH-501284 showed synergistic effects with inhibitors of EGFR, FAK/SRC, and others in combination studies. Altogether, these findings position BH-501284 as a strong candidate for further development."

Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • EGFR • HRAS • KRAS • NRAS

Key findings from the mini symposium titled 'Discovery and characterization of BH-501284: A non-covalent, pan-KRAS inhibitor for treatment of diverse KRAS-mutant tumors' (GlobeNewswire) - "BlossomHill Therapeutics presents...at AACR 2026....Median IC50 of 0.83 nM across 41 different G12/G13 KRAS mutant cell lines (excluding G12R), but sparing HRAS and NRAS (>650 nM) to avoid the toxicity of pan-RAS inhibitors....Deep tumor regression in multiple KRAS-mutant xenograft models achieved at lower doses (5-15 mg/kg BID) compared to what has been reported with other contemporary Switch-II pocket inhibitors."

Preclinical • Colorectal Cancer • Non Small Cell Lung Cancer • Pancreatic Cancer

Title: Discovery and characterization of BH-501284: A non-covalent, pan-KRAS inhibitor for treatment of diverse KRAS-mutant tumors (#6736) (GlobeNewswire) - "BlossomHill Therapeutics...announced it will introduce its next-generation KRAS pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026....BH-501284 is a potent, selective, orally available non-covalent pan-KRAS inhibitor that demonstrates picomolar binding affinity, broad activity across KRAS mutations, and durable tumor regression in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC models)."

Preclinical • Colorectal Cancer • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma